Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
Overview
The VanEck Biotech ETF (NASDAQ:BBH) offers concentrated exposure to large-cap biotech leaders, while the State Street SPDR S&P Pharmaceuticals ETF (NYSEMKT:XPH) provides broader, more diversified access to the pharmaceutical industry.
Investors seeking targeted healthcare exposure often weigh the specialized growth potential of biotechnology against the broader stability of pharmaceuticals. This comparison examines how these two industry-specific funds differ in strategy, concentration, and long-term results to help determine which approach fits a portfolio's specific needs.
Details
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-year return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
Source
Originally published at www.fool.com.